TABLE 2.
Eighteen Subjects Previously on Infliximab
| Subject | Reason for Stopping Infliximab |
Days of Infliximab | IFXL, μg/mL | ATI, U/mL | Medication(s)a | Infliximab Level (Prior Assay) | HACAb |
|---|---|---|---|---|---|---|---|
| 65 | Infusion reaction | 1987 | 11.9 | NDc | Adalimumab, budesonide, methotrexate | 1.6 | ND |
| 67 | Infusion reaction | 745 | ND | 63.7 | Methotrexate | ND | 5.74 |
| 118 | Infusion reaction | 371 | ND | ND | Thalidomide | ND | 8.26 |
| 151 | Infusion reaction | 676 | 7.1 | ND | Adalimumab, methotrexate | NAd | NA |
| 153 | Infusion reaction | 1567 | 4.4 | 8.9 | Adalimumab, methotrexate | ND | 6.45 |
| Mean (+/−SD) | 7.8 (±3.8) | 36.3 (±38.7) | 1.6 | 6.8 (±1.3) | |||
| 20 | Disease activity | 1273 | ND | ND | Tysabri | NA | NA |
| 21 | Disease activity | 188 | 34 | ND | Methotrexate, μertolizumab | ND | 8.58 |
| 26 | Disease activity | 967 | 14.4 | ND | Adalimumab | ND | 10.5 |
| 30 | Disease activity | 92 | 8 | 14.1 | Adalimumab, salicylate | ND | 8.01 |
| 42 | Disease activity | 52 | 19.4 | ND | Adalimumab | 8.3 | ND |
| 69 | Disease activity | 483 | ND | 9.4 | None, colectomy | NA | NA |
| 100 | Disease activity | 1644 | ND | ND | Tacrolimus | NA | NA |
| 139 | Disease activity | 742 | 13.2 | ND | Adalimumab | ND | 8.45 |
| 140 | Disease activity | 722 | 7.9 | ND | Adalimumab | ND | ND |
| 147 | Disease activity | 84 | ND | ND | Salicylates | NA | NA |
| 150 | Disease activity | 702 | 18.7 | ND | Adalimumab | ND | 12.18 |
| 165 | Disease activity | 497 | ND | ND | Prednisone | NA | NA |
| 178 | Disease activity | 1401 | 11.3 | ND | Adalimumab | NA | NA |
| Mean ± SDe | 832 ± 565 | 15.9 ± 8.5 | 11.75 ± 3.3 | 8.3 | 9.5 ± 1.8 | ||
a
Medications at the time of ATI and IFXL.
b
Human antichimeric antibody.
c
ND = not detected.
d
NA = no previous measurement available.
e
Mean ± SD for all 18 subjects.